Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era.

ABSTRACT: The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respir

SUBMITTER: Verdoorn BP 

PROVIDER: S-EPMC8447437 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature